Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Infect Dis ; 104: 562-567, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33476758

RESUMEN

AIMS: To develop a pharmacokinetic model of isoniazid (INH) concentration taking into account demographic factors and genetic variables [N-acetyltransferase 2 (NAT2) genotype], and to propose an initial INH dosage that could maximize the probability of achieving the desired INH concentration. METHODS: A retrospective analysis was undertaken of INH concentration data collected from patients with tuberculosis in Tunisia. RESULTS: In total, 118 patients were included in this study. The one-compartment model [volume of distribution (V), elimination rate (Ke)] was found to have good predictive performance. Multi-variate analysis showed that NAT2 affected both V and Ke significantly, but age, gender and weight did not. Internal validation of the final model showed correlation of 0.95 between individual predicted INH concentration 3 h after drug intake (C3) and observed C3. External validation showed that percentage mean absolute prediction error and percentage root mean squared error were 9.11% (range 0.62-35.8%) and 11.6%, respectively. Monte-Carlo simulation showed that doses of at least 225 mg/24 h and at least 450 mg/24 h attained a therapeutic concentration in >80% of patients in the NAT2 slow acetylator group and the NAT2 rapid/intermediate acetylator group, respectively. CONCLUSION: The pharmacokinetic model allowed optimization of individual dosing regimens of INH in patients with tuberculosis in Tunisia. This tool may facilitate improved efficacy of INH and prevent its toxicity in this population.


Asunto(s)
Antituberculosos/administración & dosificación , Antituberculosos/farmacocinética , Isoniazida/administración & dosificación , Isoniazida/farmacocinética , Tuberculosis/tratamiento farmacológico , Absorción Fisiológica , Adolescente , Adulto , Antituberculosos/sangre , Antituberculosos/uso terapéutico , Arilamina N-Acetiltransferasa/genética , Disponibilidad Biológica , Femenino , Genotipo , Humanos , Isoniazida/sangre , Isoniazida/uso terapéutico , Masculino , Persona de Mediana Edad , Modelos Biológicos , Estudios Retrospectivos , Factores Sexuales , Túnez , Adulto Joven
2.
Leukemia ; 29(2): 337-45, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24943833

RESUMEN

We examined the significance of IgM peaks in chronic lymphocytic leukemia (CLL), including its association with newly reported MYD88, BIRC3, NOTCH1 and SF3B1 mutations. A total of 27, 25, 41 and 57 patients with monoclonal IgM or IgG peaks (IgM and IgG groups), hypogammaglobulinemia (Hypo-γ group) and normal immunoglobulin serum levels (normal-γ group) were, respectively, included. IgM peaks were mainly associated with Binet stage C and the del(17p). Biased usage of IGHV3-48 was shared by both IgM and IgG groups. IGHV3-74 and IGHV4-39 gene rearrangements were specific for IgM and IgG peaks, respectively. SF3B1, NOTCH1, MYD88 and BIRC3 mutation frequencies were 12%, 4%, 2% and 2%, respectively, being over-represented in IgM, IgG and Hypo-γ groups for SF3B1, and being equal between normal-γ and IgM groups for MYD88. Overall, 76%, 87%, 49% and 42% of cases from IgM, IgG, Hypo-γ and normal-γ groups had at least one intermediate or poor prognosis genetic marker, respectively. By multivariate analysis, IgM peaks were associated with shorter treatment-free survival independently from any other univariate poor prognosis biological parameters, including IgG peaks, Hypo-γ, IGHV status, SF3B1 mutations, cytogenetics and lymphocytosis. Therefore, as with IgG peaks, IgM peaks aggravated the natural course of CLL, with increased accumulation of adverse genetic events.


Asunto(s)
Inmunoglobulina M/química , Leucemia Linfocítica Crónica de Células B/metabolismo , Anciano , Proteína 3 que Contiene Repeticiones IAP de Baculovirus , Transformación Celular Neoplásica/genética , ADN/química , Análisis Mutacional de ADN , Supervivencia sin Enfermedad , Femenino , Humanos , Inmunoglobulina G/química , Proteínas Inhibidoras de la Apoptosis/genética , Linfocitosis/genética , Masculino , Persona de Mediana Edad , Análisis Multivariante , Mutación , Factor 88 de Diferenciación Mieloide/genética , Fosfoproteínas/genética , Pronóstico , Factores de Empalme de ARN , Receptor Notch1/genética , Ribonucleoproteína Nuclear Pequeña U2/genética , Ubiquitina-Proteína Ligasas
3.
Ann Fr Anesth Reanim ; 33(5): 318-25, 2014 May.
Artículo en Francés | MEDLINE | ID: mdl-24845409

RESUMEN

OBJECTIVES: To describe the current use of epidural anesthesia (EA) apart from obstetrics, and to explain the reasons of its low utilization. STUDY DESIGN: Observational study. METHODS: A survey of practice with a self-questionnaire was sent by e-mail and available on Internet. Answers were compared between groups doing or not an epidural analgesia with exact Fisher tests (P<0.05 statistically significant). RESULTS: Among the 176 anesthesiologists who answered to the questionnaire, only 21.4% never used epidural analgesia. The main reasons were alternatives therapeutics such as PCA with opioids or TAP block (24/38 vs. 46/140). TAP block was the most common alternative used by more than 50% of anesthesiologists. Loss of competence (4/30 vs. 0/39) was rarely the reason to its low utilization. The low accessibility to specialized postoperative units was recognized in both groups as a limiting factor to do an epidural but not the fear of neurological complications. Those who never perform epidural analgesia were statistically more often physicians between 40 and 50 years (12/38 vs. 19/140). Heparin, aspirin and clopidogrel are no longer contraindications according to anesthesiologists less than 40 years old (50/68 vs. 31/68; 44/68 vs. 31/68; 37/68 vs. 23/68 respectively) but not for older. CONCLUSIONS: Epidural analgesia is performed more often by younger anesthesiologists. This survey suggests the need of specific postoperative area to allow anesthesiologist to perform and supervise safely this technique. Recommendations of the French society of Anesthesiologists are also poorly applied.


Asunto(s)
Analgesia Epidural/estadística & datos numéricos , Adulto , Factores de Edad , Anciano , Analgesia Epidural/efectos adversos , Analgesia Controlada por el Paciente/métodos , Actitud del Personal de Salud , Femenino , Francia , Encuestas de Atención de la Salud , Humanos , Internet , Masculino , Persona de Mediana Edad , Bloqueo Nervioso , Encuestas y Cuestionarios
4.
Pharmacol Res ; 72: 52-60, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23557931

RESUMEN

This study aimed to investigate the association between longitudinal exposure to mycophenolic acid (MPA) and acute rejection (AR) risk in the first year after renal transplantation, and to propose MPA exposure targets conditionally to this association. A joint model, adjusted for monitoring strategy (fixed-dose versus concentration-controlled) and recipient age, was developed; it combined a mixed-effects model to describe the whole pattern of MPA exposure (i.e. area under the concentration-time curve (AUC)) and a survival model. MPA AUC thresholds were determined using time-dependent receiver-operating characteristics (ROC) curves. Data from 490 adult renal-transplant recipients, representative of the general population of adult renal-transplant patients (i.e. including patients considered at low immunological risk-enrolled in the OPERA trial as well as second renal transplant and patients co-treated by either cyclosporine or tacrolimus), were analyzed. A significant association was found between the longitudinal exposure to MPA (MPA AUCs=f(t)) and AR (p=0.0081), and validated by bootstrapping. A significant positive correlation was observed between time post-transplantation and ROC thresholds which increased in average from 35 mg h/L in the first days to 41 mg h/L beyond six months post-transplantation (p<0.001). Using a new modeling approach which recognizes the repeated measures in a same patient, this study supports the association between MPA exposure and AR.


Asunto(s)
Rechazo de Injerto/inducido químicamente , Inmunosupresores/efectos adversos , Trasplante de Riñón , Ácido Micofenólico/efectos adversos , Adulto , Factores de Edad , Anciano , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Trasplante de Riñón/métodos , Persona de Mediana Edad , Modelos Biológicos , Ácido Micofenólico/administración & dosificación , Ácido Micofenólico/uso terapéutico , Curva ROC
5.
Cancer Imaging ; 13: 73-80, 2013 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-23466871

RESUMEN

INTRODUCTION: Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has been shown to be useful for staging and therapy response evaluation. The European Organization for Research and Treatment of Cancer (EORTC) and Positron Emission Tomography Response Criteria In Solid Tumors (PERCIST) criteria were compared in the evaluation of response assessment and prognostic factors were defined in a cohort of SCLC patients. METHODS: Twenty-nine consecutive patients with SCLC were included in this study. Sixteen patients had extensive disease and 13 had limited disease. All patients had chemotherapy, 21 had thoracic radiotherapy. FDG-PET/CT scans were performed before and after therapy to evaluate treatment response. Metabolic responses were assessed using the EORTC criteria and PERCIST criteria. Univariate and multivariate analysis were performed using a Cox model to investigate the association between progression-free and overall survival time with a number of covariates. RESULTS: There was perfect concordance between the EORTC and PERCIST criteria. Eight patients had a complete metabolic response (CMR), 9 had a partial metabolic response (PMR), 5 had stable metabolic disease (SMD) and 7 had progressive metabolic disease (PMD). Overall survival time in patients with CMR was significantly longer compared with patients who did not have CMR. The initial or delayed CMR and post-therapeutic standardized uptake value corrected for lean body mass were significantly associated with overall survival. CONCLUSION: CMR on post-therapeutic FDG-PET/CT in patients with SCLC is an important prognostic factor and may help decision making for therapeutic management.


Asunto(s)
Fluorodesoxiglucosa F18 , Neoplasias Pulmonares/diagnóstico por imagen , Imagen Multimodal/métodos , Tomografía de Emisión de Positrones , Radiofármacos , Carcinoma Pulmonar de Células Pequeñas/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Adulto , Anciano , Supervivencia sin Enfermedad , Femenino , Humanos , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Pronóstico , Carcinoma Pulmonar de Células Pequeñas/mortalidad , Carcinoma Pulmonar de Células Pequeñas/terapia
6.
Clin Pharmacol Ther ; 88(1): 95-100, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20505666

RESUMEN

Cyclosporin A (CsA) is a substrate for cytochrome P450 3A and the efflux transporter P-glycoprotein (P-gp; ABCB1), both abundantly expressed in the kidney. In a long-term follow-up of a cohort of patients who had received kidney transplants between the years 1990 and 2005, we retrospectively investigated the effect of CYP3A4, CYP3A5, and ABCB1 polymorphisms in kidney graft donors on recipients' renal function and risk of subsequent graft loss. DNA samples from 227 donors and clinical data from the 259 respective recipients were analyzed. Graft loss was significantly associated with the presence of the ABCB1 variant haplotype 1236T/2677T/3435T in the donor (1236T/2677T/3435T vs. other haplotypes: hazard ratio = 9.346; 95% confidence interval (CI) (2.278-38.461); P = 0.0019) and with previous episodes of acute organ rejection (hazard ratio = 3.077; 95% CI (1.213-7.812); P = 0.0178). The variant haplotype was also associated with a greater decrease in renal function (homozygotes for TTT -3.047 mlxmin(-1)/year; heterozygotes for TTT -4.435 mlxmin(-1)/year; others -2.186 mlxmin(-1)/year; P = 0.0240). The study showed that the presence of ABCB1 polymorphisms in donors influences long-term graft outcome adversely with decrease in renal function and graft loss in transplant recipients receiving CsA.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Ciclosporina/uso terapéutico , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/genética , Inmunosupresores/uso terapéutico , Trasplante de Riñón/fisiología , Riñón/fisiología , Polimorfismo Genético/genética , Polimorfismo Genético/fisiología , Subfamilia B de Transportador de Casetes de Unión a ATP , Adulto , Anciano , Análisis de Varianza , Estudios de Cohortes , Citocromo P-450 CYP3A/genética , Femenino , Estudios de Seguimiento , Genotipo , Haplotipos , Humanos , Estimación de Kaplan-Meier , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Donantes de Tejidos/estadística & datos numéricos , Adulto Joven
7.
Clin Pharmacol Ther ; 87(1): 100-8, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19890249

RESUMEN

The goal of this study was to determine the roles of the organic anion-transporting polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic variants in the pharmacokinetics of the immunosuppressive drug mycophenolate mofetil (MMF). Using OATP-transfected human embryonic kidney (HEK) cells, we measured the uptake of mycophenolic acid (MPA) and its glucuronide (MPAG). MPAG, but not MPA, significantly accumulated in cells expressing OATP1B3 or OATP1B1 (P < 0.05). The pharmacokinetics of both MPA and MPAG were significantly influenced by the OATP1B3 polymorphism 334T>G/699G>A in 70 renal transplant patients receiving combination treatment of MMF with either tacrolimus or sirolimus, but not in 115 patients receiving MMF and cyclosporine. The decrease in dose-normalized (dn) MPA exposure and the concomitant increase in the MPAG/MPA metabolic ratio are consistent with reduced enterohepatic cycling in patients carrying the OATP1B3 334G-699A haplotype. Further studies demonstrated that this variant of OATP1B3 exhibited a reduced maximal velocity (V(max)) in transfected HEK cells, thereby providing functional evidence to support our clinical findings.


Asunto(s)
Variación Genética/genética , Ácido Micofenólico/farmacocinética , Transportadores de Anión Orgánico/genética , Péptidos/fisiología , Línea Celular , Humanos , Transportadores de Anión Orgánico/fisiología , Péptidos/genética , Polimorfismo Genético/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA